You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨三款產品亮相TCT 2023,沛嘉醫療拉昇升超14%,為連續第二日大升
格隆匯 10-30 11:01
上週五收升近9%的沛嘉醫療-B(9996.HK)今日盤初繼續走強,一度升超11%至7.33港元,為連續第二日上升。消息面上,世界規模最大的專注於心血管介入醫學的行業盛會——美國經導管心血管治療年會(TCT 2023)於10月23-26日在舊金山盛大召開,沛嘉醫療有三款產品亮相。大會期間,中國原研器械GeminiOne的設計概念與初期臨牀結果,其原研設計特點與亮眼的臨牀數據獲得了與會專家的充分肯定。GeminiOne系統設計伊始即專注於研發一款原創器械,致力於繞過海外巨頭產品的專利限制,打造真正的FTO(Freedom-To-Operate)產品,並將成為沛嘉醫療國際化佈局的主力產品,預計於2024年開展美國EFS臨牀試驗。來自Piedmont Heart Institute的Vinod H. Thourani, MD在會中重磅揭幕了JenaValve Trilogy 的ALIGN-AR研究1年臨牀結果。目前JenaValve全球化有序推進, 2022年1月JenaValve與中國沛嘉醫療攜手簽署大中華區域獨佔許可協議,目前香港地區已開展商業化植入,中國國內上市前臨牀研究已處於入組階段有序推進中,未來JenaValve Trilogy將納入沛嘉Taurus主動脈瓣產品家族以TaurusTrio面向國內臨牀及患者。此外,在大會前沿臨牀科學與研究專場中,沛嘉醫療攜手美國醫療器械孵化器inQB8 Medical帶來創新經導管三尖瓣置換(TTVR)系統MonarQ的最新研究進展。據悉,MonarQ全新一代經導管三尖瓣置換系統的首次人體成功植入,證實了這個新系統的可行性和安全性。計劃將於2023年至2024年開始進行MonarQ TTVR系統CE和FDA的批准研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account